IBAB logo

Ion Beam Applications SA Stock Price

ENXTBR:IBAB Community·€324.9m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

IBAB Share Price Performance

€0
-13.50 (-100.00%)
€16.67
Fair Value
€0
-13.50 (-100.00%)
Price €0

IBAB Community Narratives

AnalystConsensusTarget·
Fair Value €16.67 31.8% undervalued intrinsic discount

Proton Therapy Expansion Will Transform Global Cancer Treatment

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative

Trending Discussion

Updated Narratives

IBAB logo

Proton Therapy Expansion Will Transform Global Cancer Treatment

Fair Value: €16.67 31.8% undervalued intrinsic discount
7 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with adequate balance sheet.

1 Risk
5 Rewards

Ion Beam Applications SA Key Details

€585.8m

Revenue

€400.7m

Cost of Revenue

€185.1m

Gross Profit

€168.1m

Other Expenses

€17.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Mar 27, 2026
0.58
31.60%
2.89%
32.3%
View Full Analysis

About IBAB

Founded
1986
Employees
2100
CEO
Olivier Legrain
WebsiteView website
www.iba-worldwide.com

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments in Belgium, the United States, and internationally. It operates through Proton Therapy and Other Accelerators; and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. It also develops ConformalFLASH, a novel technique using the proton Bragg peak. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Recent IBAB News & Updates

Recent updates

No updates